tetano
Editor, Senior Moderator
Neurol Clin Neurosci
. 2023 Jan;11(1):49-51.
doi: 10.1111/ncn3.12679. Epub 2022 Oct 31.
Steroid administration for post-COVID-19 Parkinsonism: A case report
Witoon Mitarnun[SUP] 1 [/SUP], Metha Apiwattanakul[SUP] 2 [/SUP], Thanatchanan Thodthasri[SUP] 1 [/SUP], Praewa Tantisungvarakoon[SUP] 1 [/SUP], Wilasinee Pangwong[SUP] 3 [/SUP]
Affiliations
Abstract
A 45-year-old man developed parkinsonism 3 weeks after being diagnosed with mild COVID-19. Levodopa and benserazide failed to improve his symptoms, necessitating ropinirole, and steroid treatment, which included a 5-day course of methylprednisolone followed by a 3-month oral prednisolone taper. One month after initiating steroid treatment, his symptoms improved significantly.
Keywords: COVID‐19; Parkinsonism; antiparkinsonian medication; severe acute respiratory syndrome coronavirus 2; steroids.
. 2023 Jan;11(1):49-51.
doi: 10.1111/ncn3.12679. Epub 2022 Oct 31.
Steroid administration for post-COVID-19 Parkinsonism: A case report
Witoon Mitarnun[SUP] 1 [/SUP], Metha Apiwattanakul[SUP] 2 [/SUP], Thanatchanan Thodthasri[SUP] 1 [/SUP], Praewa Tantisungvarakoon[SUP] 1 [/SUP], Wilasinee Pangwong[SUP] 3 [/SUP]
Affiliations
- PMID: 36714458
- PMCID: PMC9874587
- DOI: 10.1111/ncn3.12679
Abstract
A 45-year-old man developed parkinsonism 3 weeks after being diagnosed with mild COVID-19. Levodopa and benserazide failed to improve his symptoms, necessitating ropinirole, and steroid treatment, which included a 5-day course of methylprednisolone followed by a 3-month oral prednisolone taper. One month after initiating steroid treatment, his symptoms improved significantly.
Keywords: COVID‐19; Parkinsonism; antiparkinsonian medication; severe acute respiratory syndrome coronavirus 2; steroids.